S. 2295 (112th): Patient Safety and Generic Labeling Improvement Act

Introduced:

Apr 18, 2012
112th Congress, 2011–2013

Status:
Died in a previous Congress

This bill was introduced on April 18, 2012, in a previous session of Congress, but was not enacted.

Sponsor:

Patrick Leahy
Senior Senator from Vermont
Democrat

Text:

Read Text »
Last Updated: Apr 18, 2012
Length: 2 pages

About the bill

Full Title

A bill to permit manufacturers of generic drugs to provide additional warnings with respect to such drugs in the same manner that the Food and Drug Administration allows brand names to do so.

Read CRS Summary >

Related Bills

Legislative action may be ocurring on one of these bills in lieu of or in parallel to action on this bill.

H.R. 4384 (Related)
Patient Safety and Drug Labeling Improvement Act

Referred to Committee
Last Action: Apr 18, 2012

What is a bill?

The “S.” in “S. 2295” means this is a Senate bill in the United States Congress. A bill must be passed by both the House and Senate in identical form and then be signed by the President to become law.

The bill’s title was written by its sponsor.

History

Introduced
Apr 18, 2012

Details

Cosponsors
7 cosponsors (7D) (show)
Committee Assignments

The committee chair determines whether a bill will move past the committee stage.

Votes

There have been no votes related to this bill.

Subject Areas
Find Similar Bills

Search for similar bills.

Links & tools

Primary Source

THOMAS.gov (The Library of Congress)

GovTrack gets most information from THOMAS, which is updated generally one day after events occur. Activity since the last update may not be reflected here. Data comes via the congress project.

Citation

Click a format for a citation suggestion: